Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13530514 | 0.92 | KDM4E (0.42) | CNR1STK17ACNR2HSD17B10KDM4E | |
| SCHEMBL13530553 | 0.90 | CNR1 (0.43) | CNR1STK17ACNR2MAPK1 | |
| SCHEMBL13530543 | 0.89 | VNN1 (0.45) | CNR1STK17ACNR2MAPK1KDM4E | |
| SCHEMBL13530637 | 0.87 | POLB (0.43) | CNR1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL13530598 | 0.87 | POLB (0.43) | CNR1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL13530526 | 0.86 | CNR1 (0.46) | CNR1CNR2 | |
| SCHEMBL13530611 | 0.85 | L3MBTL1 (0.53) | KDM4EALDH1A1EGFR | |
| SCHEMBL13530517 | 0.85 | CNR1 (0.52) | CNR1CNR2EGFR | |
| SCHEMBL13530645 | 0.85 | CLK4 (0.48) | CNR1CNR2EGFR | |
| SCHEMBL13530658 | 0.85 | KMT2A (0.43) | CNR1CNR2KDM4EALDH1A1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9204653-B2 | 5-fluoro pyrimidine derivatives | DOW AGROSCIENCES LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9174970-B2 | 5-fluoro pyrimidine derivatives | DOW AGROSCIENCES LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174970-B2 | 5-fluoro pyrimidine derivatives | DOW AGROSCIENCES LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140024616-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090203647-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203647-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009094442-A2 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DPYD, DPM1, DDX5 | CNR1 4592/4885STK17A 3247/4885CNR2 4527/4885 |
| US-20140024616-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DPYD, DPM1, DDX5 | CNR1 4592/4885STK17A 3247/4885CNR2 4527/4885 |
| US-20090203647-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DPYD, DPM1, DDX5 | CNR1 4592/4885STK17A 3247/4885CNR2 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.